Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
7,319 total articles
Uber is trading near $74.70 with a market cap around $152B, a P/E near 15-16 and strong free cash flow. Ahead of Q1 results, the setup favors a long swing: improving monetization from advertising and AI, continued recovery in mobility, and secular growth in India delivery. Trade plan: enter at $74.50, stop $68.00, target $95.00 for a mid-term hold …
RLLCF is a deeply discounted preferred class trading OTC. Technical momentum is turning constructive, short interest is concentrated, and price sits near near-term support. This trade treats the position as a high-risk, high-reward asymmetric bet: small capital outlay for meaningful upside if corporate news or buying pushes liquidity and sentiment.
Aker BP is positioned to benefit from renewed European energy tightness and favorable oil/gas pricing. We maintain a Buy stance: enter $28.50, target $40.00, stop $24.00 over a long-term (180 trading day) horizon. The thesis rests on high-quality North Sea assets, conservative capex, and shareholder returns — with catalysts in production updates an…
Paycom has been punished by growth deceleration, index removal and AI worries, yet it still generates strong free cash flow, carries no debt and trades at single-digit EV/EBITDA and low-teens P/E. This trade targets a rebound over the next six months while keeping a tight, objective stop.
Apollo Global Management ($128.72) offers a rare asymmetric opportunity: high-margin, fee-bearing private credit and yield businesses that have been discounted due to headline legal risk and sector chatter. With a $74.2B market cap, attractive cash metrics and a tangible runway to recover AUM and fees, I initiate a tactical long: entry $128.72, tar…
Broadcom is rallying on AI infrastructure demand and still offers a favorable asymmetric trade: robust cash generation, double-digit ROE, and rising technical momentum justify a tactical long. Entry at current levels, tight stop, and ambitious target capture continued multiple expansion plus business growth tied to hyperscaler AI spend.
Bombardier (BDRAF) has ripped higher today to $211.30, clearing key moving averages and putting momentum indicators into bullish territory. Thin OTC liquidity, periodic spikes in short interest and the recent surge in price create a path where further re-rating and corporate actions aimed at returning capital become more probable. This note lays ou…
DraftKings (DKNG) is a market leader in digital sports wagering and casino, but valuation and capital structure no longer match the business profile. With EV of roughly $12.3B, a high EV/EBITDA of 47.4x and a current ratio under 1.0, the stock looks exposed to downside if growth slows or regulatory tailwinds fade. This trade idea proposes a tactica…
Wayfair has pulled back after a blistering 2025-2026 run. With improving margins, positive free cash flow of $464M and a valuation below 1x price-to-sales, this dip looks like a tactical buying opportunity for traders who can stomach volatility. I outline a clear entry at $64.00, a stop at $58.00 and a target of $95.00 over a mid-term 45 trading da…
Townsquare Media (TSQ) is a small-cap, community-focused media company whose digital transformation is now producing recurring revenue and strategic partnerships. With digital above 50% of revenue, a recent alliance with Kroenke Sports & Entertainment, a market cap near $111M and a double-digit yield, TSQ offers an asymmetric mid-term trade: income…
Brown-Forman's collapse of merger talks with Pernod Ricard and a competing $32 cash bid from Sazerac left the stock without a clear path to a takeover premium. Fundamentals show solid free cash flow but limited upward catalysts, while technical momentum and heavy short activity point to a mid-term pullback. This trade idea sells BF.B at $25.80 with…
Bandwidth (BAND) is ripping higher today on heavy volume as the market begins to reward improving enterprise adoption and cash flow. The setup is a tactical swing trade: buy into strength at the market, protect with a tight stop below recent intraday lows, and target a materially higher multiple as adoption and partnership contribution become visib…
Eagle Materials (EXP) looks ready for an upgrade. Record revenue, strong free cash flow and healthy returns combine with attractive earnings multiple and improving technicals. This trade idea outlines a mid‑term long with clear entry at $205.00, stop at $195.00 and a $250.00 target over the next 45 trading days.
Royal Caribbean (RCL) looks set to keep recovering its pricing power despite near-term oil volatility. The company trades at a reasonable P/E (~16x) with strong ROE (42.5%) and positive free cash flow. We present a mid-term trade: entry $265.00, target $320.00, stop $242.00, horizon mid term (45 trading days).
Amazon's valuation already prices it as a cash-generative tech platform, but accelerating AI adoption across enterprises - and clear signs AWS can convert that demand into revenue - make a tactical long attractive. Entry at $265, target $320, stop $245; horizon: long term (180 trading days).
eBay looks like a constructive buy here: the company combines high returns on equity, steady free cash flow generation and shareholder-friendly buybacks with a refreshed growth runway (Depop acquisition and focus on collectibles). At roughly $104 per share, the stock trades at mid-20s P/E and an EV/EBITDA below 19, offering a favorable risk-reward …
Zenas BioPharma is a high-conviction long because management has secured new financing, is preparing a BLA filing for obexelimab, and expects Phase 2 lupus data by year-end 2026. The market has punished the stock after a disappointing IgG4-RD Phase 3 readout, leaving upside if obexelimab shows meaningful activity in SLE or if the FDA engagement aro…
Nuvalent is a clinical-stage precision oncology company with two lead kinase programs that have near-term regulatory and pivotal catalysts in 2026. The stock trades at about $99.35 with a market cap near $7.85B and roughly $2.87B in cash on the balance sheet. This trade idea is a directional long into upcoming FDA decisions and program readouts, wi…
Meta beat Q1 expectations with 33% revenue growth to $56.31B and sharply higher EPS, yet shares plunged after management raised 2026 capex to $125-145B. That capex is largely AI infrastructure spending that should expand long-term TAM and protect margins vs. competitors. This trade idea buys the selloff with a clear entry, stop and target aligned t…
Cullinan Therapeutics is a clinical-stage oncology and immuno-oncology company trading at roughly $790M market value while sitting on a large cash position. Positive pivotal data in its zipalertinib program and multiple clinical readouts set up a potential 2027 FDA catalyst. For traders willing to accept clinical binary risk, a mid-term long (45 tr…
Svenska Handelsbanken has the balance-sheet profile and business mix to weather renewed macro volatility. This trade idea recommends a long position with a clearly defined entry at $9.00, a stop at $7.80 and a primary target of $11.25 over a 180-trading-day horizon, aiming to capture a re-rating tied to stable profitability, steady dividend support…
QXO recently agreed to buy TopBuild for $17 billion, creating a much larger building-products distributor. The market punished QXO shares on dilution and leverage concerns, but the combined company will generate roughly $18 billion in revenue and target $300 million in synergies by 2030. With a market cap near $14.36B and free cash flow of $183.2M,…
Solid Power is showing incremental progress toward commercializing solid-state EV cells. Balance-sheet liquidity, a design that targets factory compatibility, and improving market sentiment create a tactical buying opportunity. This trade lays out an entry at $3.47, a $5.25 target and a $2.70 stop over a mid-term (45 trading days) horizon.
Eli Lilly's Q1 performance and the retatrutide clinical headline put the company in a class of its own. The stock is trading at $931.64 with a market cap near $880B, rich multiples but justified by blockbuster growth prospects and strong cash generation. This is a position trade: buy at market, stop at $870, target $1,100 over the next 180 trading …
FTAI Aviation ($FTAI) is firing on multiple cylinders: a growing engine leasing and MRO footprint, an expanding feedstock pipeline from recent Air France deals, and promising unit-conversion growth through FTAI Power and data-center partnerships. The stock is richly valued, but current upside is supported by concrete business drivers. We lay out a …
